Had previously guided for FY25 Ingrezza net product sales of $2.5B-$2.6B. FY25 revenue consensus $2.69B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine reports Q2 non-GAAP EPS $1.65, consensus $1.50
- Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 3 Study
- These 3 Stocks are Screaming ‘Strong Buy,’ According to the Technical Analysis
- Strong Market Position and Growth Potential for Neurocrine’s Ingrezza
- Promising Future Prospects for Neurocrine: Buy Rating Affirmed by Analyst Marc Goodman